Use of flucinolone acetonide for patients with diabetic macular oedema: Patient selection criteria and early outcomes in real world setting

BMC Ophthalmology

Volumn 16, Issue 1, 2016, Pages

  Elaraoud, Ibrahim ^a   Andreatta, Walter ^a   Kidess, Andrej ^b   Bhatnagar, Ajay ^a   Tsaloumas, Marie ^b   Quhill, Fahad ^c   Yang, Yit ^a,d  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

Diabetic macular oedema; Fluocinolone Acetonide; Iluvien; Patient selection, early clinical outcome, visual acuity, central retinal thickness

Indexed keywords

DRUG IMPLANT; FLUOCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; AGED; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG IMPLANT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACULAR EDEMA; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATIENT SELECTION; RETINA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PATIENT SELECTION; RETINA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84959210107     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-015-0178-9     Document Type: Article

References (17)

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64.
2. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151-69.
3. Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond). 2012;26 Suppl 2:S1-16.
4. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013-22.
5. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375-81. doi: 10.1016/j.ophtha.2014.08.047. Epub 2014 Oct 28.
6. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Comparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-203. doi: 10.1056/NEJMoa1414264.
7. Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S, Beck R, Aiello LP, Antoszyk A, et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology. 2007;114(6):1190-6.
8. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125-32.
9. Ozurdex MEAD Study Group, Boyer D, Yoon Y, Belfort R, Bandello F, Maturi R, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2011;118:626-35.
10. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). Accessed on 19 April 2015 < https://www.nice.org.uk/guidance/ta301 >.
11. FDA approval of Flucinolone Acetonide in treatment of diabetic macular oedema. Accessed on 19 April 2015 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails >.
12. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046-50. doi: 10.1097/IAE.0b013e3181d87e04. Jul-Aug.
13. Snellen - logMAR Visual Acuity Calculator. Last accessed 19 April 2015 < http://www.myvisiontest.com/logmar.php >.
14. Personal communications with F Quhill(Sheffield), A Bhatnagar (Wolverhampton and M Tsaloumas (Birmingham) 2015.
15. Levin DS, Han DP, Dev S, Wirostko WJ, Mieler WF, Connor TB, et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol. 2002;133(2):196-202.
16. Thomas Bertelmann. Stephan Schulze long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Ther. DOI 10.1007/s40123-015-0028-0.
17. Campochiaro PA1, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Ophthalmology. 2011;118(4):626-635.e2. doi: 10.1016/j.ophtha.2010.12.028.